Biogen’s Tecfidera Sales Growth Moderating In U.S., But Sales Still Stellar
This article was originally published in The Pink Sheet Daily
The growth of Biogen Idec’s blockbuster pill for multiple sclerosis began to moderate in the U.S. in the fourth quarter, which the company attributed to a decline in the overall switch rate, a label update and the launch of its own next-generation interferon Plegridy.
You may also be interested in...
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.
US vaccination campaign will pick up speed now that access is broadening, leaders from Operation Warp Speed, Pfizer, Moderna, McKesson and CVS Health say at a J.P. Morgan panel discussion.
Vir believes its single antibody will be effective against rising mutant forms of COVID-19. Phase III data from two ongoing trials are expected in the first quarter.